Synta Pharmaceuticals Reports On Progress With Lead HDC Compounds At IASLC Conference

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) today reported on progress with lead compounds from its Hsp90-Inhibitor Drug Conjugate (HDC) platform at the IASLC 14th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, California. The new compounds, consisting of an Hsp90-inhibitor conjugated with SN-38 (HDC SN-38) and an Hsp90-inhibitor conjugated with docetaxel (HDC docetaxel), demonstrated proof of principle in multiple preclinical cancer models.

Help employers find you! Check out all the jobs and post your resume.